Efficacy and Safety of Gemcitabine-Docetaxel Combination Therapy for Recurrent or Refractory High-grade Osteosarcoma in China: A Retrospective Study of 18 Patients
Open Access
- 26 March 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 42 (5) , 427-431
Abstract
In this study, we describe experiences with gemcitabine–docetaxel combination therapy as salvage treatment for Chinese patients with recurrent or refractory high-grade osteosarcoma. We retrospectively reviewed the medical records of 18 patients with recurrent or refractory high-grade osteosarcoma who had undergone gemcitabine–docetaxel combination treatment as salvage chemotherapy. Gemcitabine at 675 mg/m2 was administered on Days 1 and 8, and docetaxel at 75–100 mg/m2 was administered on Day 8. The combination therapy was repeated every 3 weeks. Treatment was continued until evidence of disease progression or unacceptable toxicity. The patients (ages 12–57 years) received a total of 44 cycles of chemotherapy (median: 2 courses; range: 2–6 courses). The overall response rate was 5.6% and the disease control rate was 22.3%, with one partial response and three patients with stable disease. The median time to progression and overall survival time were 2 months (range: 2–6 months) and 8 months (range: 3–21 months), respectively. Major severe toxicities were hematologic toxicities, including Grade 3 or 4 anemia (9.1%), leucopenia (29.5%) and thrombocytopenia (18.1%) in total cycles; mild toxicities included Grade 1 or 2 nausea and vomiting (31.8%), fatigue (38.6%) and alopecia (20.5%). There were no treatment-related deaths. In the current study, gemcitabine–docetaxel combination therapy at this dosage and schedule was found to be well tolerated and marginally effective, which could be considered as salvage therapy for patients with recurrent or refractory high-grade osteosarcoma.Keywords
This publication has 16 references indexed in Scilit:
- Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamideAsia-Pacific Journal of Clinical Oncology, 2011
- Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and DocetaxelJournal of Pediatric Hematology/Oncology, 2009
- Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcomaCancer, 2008
- Docetaxel and Gemcitabine in the Treatment of Soft Tissue Sarcoma – A Single-Center ExperienceOnkologie, 2008
- Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002Journal of Clinical Oncology, 2007
- Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of SarcomaJournal of Clinical Oncology, 2004
- Osteosarcoma in the first decade of lifeMedical and Pediatric Oncology, 2003
- Phase II trial of gemcitabine in advanced sarcomasCancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of TaxolJNCI: Journal of the National Cancer Institute, 1991